Press Releases

Home / Investor Relations / Press Releases

Language

Category

Year

2023-02-02 07:31 Boule Diagnostics (publ) Year-end report January–December 2022 Regulatory

Improved gross margin for the quarter Quarter October-December 2022 Full year January–December 2022 * A bonus issue element from the new share issue in Q4 2022 has been taken into account in the calculation of earnings per share before and after dilutive...

2023-01-26 15:01 Boule Diagnostics – Invitation to presentation of the year-end report 2022

Boule Diagnostics AB will publish the year-end report for the period January – December 2022 at 07:30 CET, Thursday, February 2nd, 2023. Following the publication, Boule will hold a Teams Live Event at 10:00 for media and investors. CEO Jesper Söderqvist...

2022-12-30 15:01 Change in number of shares and votes in Boule Diagnostics Regulatory

Stockholm, Sweden, December 30, 2022 – Boule Diagnostics AB (publ) (“Boule” or the “Company”) (Nasdaq Stockholm: BOUL) has, as previously announced, carried out a preferential rights issue of shares, which has resulted in changes in the number...

2022-12-14 08:01 Boule Diagnostics appoints Jan Benjaminson as interim CFO

Boule Diagnostics AB has today appointed Jan Benjaminson as interim CFO, effective on February 3rd, 2023. Jan will succeed Annette Colin who will continue as CFO up to and including the same date. Jan has been active in several listed companies, both...

2022-11-30 08:01 Boule Diagnostics raises approximately SEK 150 million through a significantly oversubscribed rights issue Regulatory

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE...

2022-11-28 07:31 Boule receives CE mark according to IVDR Class B for two product lines

Boule Medical AB has reached another important milestone in its preventive and diligent work in meeting the new and increased regulatory requirements for in vitro diagnostics. Boule has received CE mark according to IVDR class B for two of its product...

2022-11-14 15:21 Trading of subscription rights commences Tuesday 15 November

2022-11-10 14:21 Boule Diagnostics publishes prospectus in connection with its Rights Issue

2022-11-10 07:31 Boule Diagnostics (publ) Interim report January–September 2022 Regulatory

A challenging third quarter Quarter July-September 2022 CEO Jesper Söderqvist Sales increased by 12 percent to SEK 126 million. Adjusted for exchange rates, organic growth decreased by 8.1 percent. This decrease is due to the challenging market conditions...

2022-11-07 15:01 Boule Diagnostics – Invitation to presentation of the interim report Q3 2022

Boule Diagnostics AB will publish the interim report for the period January – September 2022 at 07:30 CET, Thursday, November 10th, 2022. Following the publication, Boule will hold a Teams Live Event at 10:00 for media and investors. CEO Jesper Söderqvist...

2022-11-01 18:31 Bulletin from the extraordinary general meeting in Boule Diagnostics on November 1, 2022

Boule Diagnostics AB (”Boule”) held an extraordinary general meeting today November 1, 2022 (”EGM”). The complete proposals regarding the resolutions have been published previously and are available on Boule’s website, www.boule.com. Amendment...

2022-10-28 15:01 Boule Diagnostics – Nomination Committee for the 2023 Annual General Meeting

The Annual General Meeting, (”AGM”), 2022 of Boule Diagnostics AB (publ), (”Boule”), decided that a Nomination Committee based on the ownership structure as per September 30, 2022, will be appointed to propose for the AGM of 2023 the following...

2022-10-20 08:01 Boule sets up contract manufacturing of reagents in India

Boule Diagnostics has signed a strategic contract manufacturing agreement with Q-Line Biotech for local hematology reagent manufacturing in India. India is a large and important market with over 30 million tests per year conducted using Boule's automated...

2022-10-03 08:01 Boule Diagnostics resolves on a fully secured preferential rights issue of approximately SEK 150 million Regulatory

2022-09-06 13:00 Clinical Diagnostic Solutions has been issued a Notice of Inspectional Observations by FDA

Clinical Diagnostic Solutions, Inc. (CDS), a subsidiary to Boule Diagnostics AB, has been issued a Notice of Inspectional Observations (FDA Form 483) by the US Food and Drug Administration (the FDA). After a routine inspection of CDS’ operations, inspectional...

2022-08-04 22:01 CFO Annette Colin leaves Boule due to family reasons Regulatory

Annette Colin has today informed Boule Diagnostics that she is leaving the position as CFO due to family reasons. Annette will continue in her role during her six-month notice period in order to ensure an orderly transition period up until a new CFO assumes...

2022-07-18 07:31 Boule Diagnostics (publ) Interim report January–June 2022 Regulatory

Continued growth for all products

2022-07-14 15:01 Boule Diagnostics – Invitation to presentation of the interim report Q2 2022

Boule Diagnostics AB will publish the interim report for the period January–June 2022 at 07:30, Monday, July 18th, 2022. Following the publication, Boule will hold a Teams Live Event at 10:00 for media and investors. CEO Jesper Söderqvist and CFO...

2022-05-05 19:31 Bulletin from Annual General Meeting in Boule Diagnostics AB on May 5, 2022

The Annual General Meeting 2022 (the ”AGM”) decided to adopt the balance sheet, income statement, consolidated income statement and consolidated balance sheet for 2021. Furthermore, a dividend to shareholders of SEK 0.55 was approved for 2021 and...

2022-05-04 10:01 Boule Diagnostics (publ) Interim report January–March 2022 Regulatory

Double digit growth for all products Quarter January-March 2022 CEO Jesper Söderqvist Strong growth in sales and improved operating profit Boule started the year with strong growth in sales. We recorded our highest net sales for a first quarter, just...

Previous Next